Posted on

Nick Karos To Present At H.c. Wainwright 1st Annual Mental Health Conference

Nick Karos To Present At H.c. Wainwright 1st Annual Mental Health Conference

Calgary, AB – TheNewswire – June 24, 2022 – Universal Ibogaine Inc. (TSXV:IBO ) , ( OTC:IBOGF ) and ( FSE:JC4) (“ UI ” or the “ Company ”) a life sciences company with a mission to transform addiction treatment using medicalized ibogaine and a global licensing model is pleased to announce that Nick Karos, CEO will present at the H.C. Wainwright 1 st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond.  The event is a hybrid online and in person event scheduled for June 27, 2022.

About H.C. Wainwright

H.C. Wainwright & Co is one of the oldest and most trusted names in corporate finance in the USA providing investment banking, corporate advisory, research, and analysis covering sectors including Healthcare & Life Sciences, Mining, Cleantech, Shipping & Maritime and Technology.

H.C. Wainwright hosts a robust calendar of conferences and events in the Healthcare sector.  More information and registration for the 1 st Annual Mental Health Conference can be found here .

Nick Karos CEO of Universal Ibogaine commented “H.C. Wainwright is a leader in the space and could be a strong strategic partner in our ongoing corporate finance roadmap.  The opportunity to tell our story to this audience is another important step in developing the awareness around brand and offering.

Correction Notice June 13 Blue Digital Media

In UI’s June 13, 2022 News Release it was stated that stock options to be granted to investor relations advisory firm Blue Digital Media would vest one-third at the end of each month in the 3 month term of service. Under TSXV Exchange Policy 4.4 Security Based Compensation, stock options for investor relations firms must vest quarterly over a 12 month period with the first vesting for 25% of the options at 3 months,25% at 6 months, 25% at 9 months and the final 25% at 12 months.

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

For further information:  

Investor Relations: Dugan Selkirk, Investor Relations Manager 

dugan.selkirk@universalibogaine.com 

Related Links  https://universalibogaine.com

Posted on

Universal Ibogaine Retains Shayne Nyquvest As Capital Markets Advisor

Universal Ibogaine Retains Shayne Nyquvest As Capital Markets Advisor

Calgary, AB – April 29, 2022 – Universal Ibogaine Inc. (TSXV:IBO, OTCQB:IBOGF and FSE:JC4) (“UI” or the “Company”) a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has retained Mr. Shayne Nyquvest in a consulting role as Capital Markets Advisor.

Mr. Nyquvest has extensive capital markets experience, with over 40 years involvement in aiding companies strategic fund-raising activities, in the mining, cannabis and other emerging industries.  He served as the former Executive Vice-President of investment banking firm Mackie Research Capital (where he worked from June 2015 to July 2018) and a was founding member of Canaccord Genuity Group, where he worked as a Senior Investment Advisor from 1993 to 2013. 

Mr. Nyquvest cofounded UI in early 2018, after personally seeing the transformational effects and potential of ibogaine, and was involved in UI’s early stage development until mid-2021.  His vision has been to see this innovative, plant-based treatment adopted by the mainstream medical community as a solution to helping break the opioid epidemic and other addictions.

Nick Karos, UI CEO noted “we are pleased to have Shayne re-engaged in our strategic, business development goals.  He has an extensive network in the investment community, and was instrumental in UI’s early stage financing and research activities.  We continue to advance our planned Health Canada clinical trials application for the use of ibogaine in opioid use disorder, and expect to provide additional updates on this in the near future.”

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial (focused on opioid use disorder), and ultimately to utilize that protocol around the globe through planned future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction. 

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

For further information:

Investor Relations: Dugan Selkirk, IR Manager

dugan.selkirk@universalibogaine.com

Posted on

Universal Ibogaine Announces Frankfurt Stock Exchange Listing

Universal Ibogaine Announces Frankfurt Stock Exchange Listing

Calgary, AB – April 5, 2022 – Universal Ibogaine Inc. (TSXV:IBO and OTCQB: IBOGF and FSE: JC4) (“UI” or the “Company”) a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares have been approved for trading on the Frankfurt Stock Exchange, or Bourse Frankfurt (the “FSE”) under the ticker symbol “JC4”.  UI will continue to trade in Canada on the TSX Venture Exchange under its current ticker symbol IBO and on the OTCQB under the ticker symbol IBOGF. 

The FSE is the largest stock exchange in Germany and is the premiere European destination for Canadian Venture companies looking to build exposure and liquidity with the European market.  The FSE facilitates advanced electronic trading, settlement and information systems allowing it to meet the growing requirements of cross-border trading.

Global Addiction and the Overdose Crisis

According to an August 4, 2021, World Health Organization report, worldwide approximately 500,000 deaths annually can be attributed to drug use, with more than 70% related to opioids. 

“The number of opioid overdoses has increased in recent years in several countries, in part due to the increased use of opioids in the management of chronic pain and increasing use of highly potent opioids appearing on the illicit drug market.

In the United States of America (USA) the number of people dying from opioid overdose increased by 120% between 2010 and 2018, and two-thirds of opioid-related overdose deaths in 2018 in the USA involved synthetic opioids, including fentanyl and its analogues.

During the COVID-19 pandemic, a further substantial increase in drug overdose deaths was reported in the USA, primarily driven by rapid increases in overdose deaths involving synthetic opioids.”

What is ibogaine?

Ibogaine is a plant derived neuroactive compound that appears to reset the brains of drug dependent individuals to a pre-addicted state and has demonstrated particular effectiveness in treating opioid use disorder in many countries.  When applied according to a strict safety protocol, including a medically supervised setting, ibogaine appears to eliminate the most painful symptoms of opioid withdrawal and can provide a several month window free of drug cravings.  Dr. Alberto Sola, co-founder and member of the Board of Directors of Universal Ibogaine, has administered more ibogaine treatments than any other doctor in the world at an independent clinic (of which he is a partner) in Cancun, Mexico. 

The Universal Ibogaine Mission

Universal Ibogaine is a Canadian company which holds the global licensing rights to the ibogaine based addiction treatment protocol developed by Dr. Alberto Sola.  UI is working with Health Canada to undertake a planned clinical trial in Canada to demonstrate the safety and efficacy of the ibogaine treatment protocol for opioid use disorder(s).  Upon eventual completion of the trial and Health Canada approval, UI intends to license the protocol to a global network of addiction treatment clinics.  Ibogaine can be very effective for long term addiction cessation when combined with an aftercare treatment program.  Universal Ibogaine operates an addiction treatment facility in Winnipeg, where it is intends to develop best in class addiction treatment programs built around evidence based treatments and nuovo modalities. 

Universal Ibogaine CEO Nick Karos commented “the FSE listing is a key piece of our capital markets and investor relations strategy.  We have recently commenced trading on the OTCQB Exchange in the USA, and interest in the UI story is growing in Europe and Germany in particular.  Germany has a history of innovation and leadership with an emerging market and interest in psychedelic medicines.”

About Universal Ibogaine Inc. 

UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial, and ultimately to utilize that protocol around the globe through future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Clinic that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction. 

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.  

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS  

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.  

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎ 

For further information:  

Investor Relations: Dugan Selkirk, IR Manager 

dugan.selkirk@universalibogaine.com

Medical Contact: Hirpal Hundial, Director – Clinical Services

hirpal.hundial@universalibogaine.com  

Posted on

Universal Ibogaine To Present At Otc Virtual Investor Event

Universal Ibogaine To Present At Otc Virtual Investor Event

Universal Ibogaine Inc. to Webcast Live at OTC Markets VirtualInvestorConferences.com March 10th

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

Calgary, AB Canada, March 08, 2022 — Universal Ibogaine (OTCQB:IBOGF TSXV:IBO FSE:JC4), a life sciences company based in Canada, focused on transforming the addiction treatment industry through the medical use of the plant medicine ibogaine, today announced that Nick Karos Name, Chief Executive Officer, will present live at OTC Markets VirtualInvestorConferences.com on March 10th, 2022.

DATE: March 10th, 2022

TIME: 12:00 PM EST

LINK: https://bit.ly/3LRhCdu

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

Event attendees will also be able to schedule 1 on 1 meetings with the Investor Relations team which will take place on Friday March 11, Monday March 14, and Tuesday March 15.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

Recent Company Highlights

About Universal Ibogaine


Universal Ibogaine is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a planned Canadian Clinical Trial, and ultimately to utilize that protocol around the globe through future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Clinic that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction. 

About Virtual Investor Conferences

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access.  Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

CONTACTS:

Universal Ibogaine

Dugan Selkirk

Investor Relations Manager

1-855-426-4246

dugan.selkirk@universalibogaine.com

Virtual Investor Conferences

John M. Viglotti

SVP Corporate Services, Investor Access

OTC Markets Group

(212) 220-2221

johnv@otcmarkets.com